BioWatch Update - The Less Known Indications | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website
  • TECH UPDATE: Please accept our apologies for the delay in getting our "board visit & message view" counts to normalize. As you may have noticed, starting yesterday the "board stats" for individual message boards started to display clearly erroneous "member" and "guest" visit counts. Needless to say, we don't like having unreliable traffic stats on the site any more than you do. Please understand this was not by design or intention. It's a glitch that resulted from an apparent incompatibility with the legacy code and the recent deployment of new servers to tackle issues related to last month's outage. In order to give our web developer a chance to take a closer look at the glitch and come up with a viable solution, we have decided to leave the code up for now so she can have real-world data to work with (rather than just turn the counts off again). So it looks like we may have to live with these bad counts a little longer, but our expectation is to have this resolved by early next week, if not sooner. We appreciate your patience and understanding.  

CORT   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3305 of 3333  at  9/22/2020 3:15:24 AM  by


The following message was updated on 9/22/2020 3:22:19 AM.

 In response to msg 3304 by  i760
view thread

Re: BioWatch Update - The Less Known Indications

First, you are correct. The obvious indications are addressed in the expanded document. However, if anyone wants to search for information regarding pancreatic and ovarian cancer, I devoted oprior articles to each cancer.  
Second, the focus on the "less known" indications enabled a different lens on the valuation. You are able to see Corcept "playing the odds", This becomes clearer by focusing on these indications, and "playing the odds" becomes a consistent theme. We know that Corcept minimized financial risk through the use of independent investigators. At the same time, it has a large set of clinical trials in play. The results should arrive by Year-End 2022 for the entire set. 
Third, there may be a day in which I do an update with the "obvious indications" again. The expanded document stands at 34 pages. Remember my review articles on Ovarian Cancer and Pancreatic Cancer? Each was fairly lengthy. Nevertheless, you can extrapolate if you thoughtfully extrapolate from the condensed update. Let me provide hints.
CORT valuation is maintained and advanced even it GRACE & GRADIENT are the only successes - even if all the lesser known indications fail, and perhaps even if RELIANT and Ovarian fail too.

What are the implications of that statement? This describes a good situation doesn't it?

In the expanded document, I also turn the statement on its head. How can CORT keep its valuation if GRACE & GRADIENT fail? 

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 119
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
3307 Re: BioWatch Update - The Less Known Indications - recommended i760 1 9/22/2020 12:29:38 PM

Financial Market Data provided by